Gerber Kawasaki Wealth & Investment Management Trims Stock Position in Zoetis Inc. (NYSE:ZTS)

Gerber Kawasaki Wealth & Investment Management lessened its position in shares of Zoetis Inc. (NYSE:ZTS) by 23.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,344 shares of the company’s stock after selling 3,473 shares during the period. Gerber Kawasaki Wealth & Investment Management’s holdings in Zoetis were worth $1,848,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC grew its holdings in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 140 shares in the last quarter. Rakuten Securities Inc. lifted its position in Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 166 shares during the last quarter. Murphy & Mullick Capital Management Corp purchased a new position in Zoetis in the 4th quarter worth approximately $44,000. Asset Planning Inc bought a new position in shares of Zoetis in the 4th quarter worth $58,000. Finally, Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of Zoetis during the 4th quarter valued at $59,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. This trade represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock worth $312,254 in the last 90 days. Company insiders own 0.16% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $153.58 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The firm has a market cap of $68.52 billion, a PE ratio of 28.08, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92. The business has a 50 day moving average price of $158.91 and a 200-day moving average price of $168.47.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.30%. Zoetis’s payout ratio is presently 36.56%.

Analysts Set New Price Targets

Several research analysts recently issued reports on ZTS shares. Morgan Stanley cut their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Stifel Nicolaus cut their price objective on Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a report on Monday, April 14th. Barclays raised their price objective on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Finally, Piper Sandler increased their price target on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $214.40.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.